<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04321837</url>
  </required_header>
  <id_info>
    <org_study_id>AAAS2051</org_study_id>
    <secondary_id>HS# 2018-4772</secondary_id>
    <nct_id>NCT04321837</nct_id>
  </id_info>
  <brief_title>Coral Calcium's Effect on Bone Density in Postmenopausal Women With and Without Ibandronate</brief_title>
  <official_title>Coral Calcium's Effect on Bone Density in Postmenopausal Women With and Without Ibandronate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of California, Irvine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Osteoporosis Center of Armenia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the effect of coral calcium complex supplementation on BMD of
      osteoporotic individuals either when used alone or in combination with ibandronate.
      Ibandronate alone will also be tested in comparison to coral calcium supplementation alone or
      in combination.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Osteoporosis and resulting fragility fractures are major causes of morbidity and mortality in
      older individuals. Current estimates indicate that as many as 50% of American women and 20%
      of men over the age of 50 will be at risk for osteoporotic fractures during their lifetimes,
      and that these fractures are associated both with higher risk for further fractures and with
      higher mortality rates. Osteoporosis and subsequent fragility fractures can be prevented if
      diagnosed and treated appropriately. The first step of treatment guidelines for individuals
      with reduced bone mineral density (BMD), as identified with dual energy x-ray absorptiometry
      (DXA) scan, is the implementation of lifestyle measures to reduce bone loss. These include
      the supplementation of dietary calcium and vitamin D to maintain appropriate calcium intake
      and reduce resorption of mineralized calcium from bone. Pharmacological treatment can be used
      for the treatment of osteoporosis in individuals who have reduced BMD (less than -2.5
      T-score) and for those who have sustained a fragility fracture. The bisphosphonates are first
      line agents for the treatment of osteoporosis. Coral-derived calcium is a novel formulation
      of calcium supplement, which has not yet been rigorously investigated as an efficacious
      nutrient for the skeleton. Ibandronate is a commonly available bisphosphonate prescribed for
      the treatment of osteoporosis. Vitamin D is a nutrient required to absorb vitamin D from the
      diet.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 5, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in bone mineral density (BMD) (lumbar spine)</measure>
    <time_frame>48 weeks</time_frame>
    <description>Participant bone mineral density of lumbar spine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change in BMD (femoral neck)</measure>
    <time_frame>48 weeks</time_frame>
    <description>Participant bone mineral density of femoral neck.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change in BMD (total hip)</measure>
    <time_frame>48 weeks</time_frame>
    <description>Participant bone mineral density of total hip.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change in BMD (forearm)</measure>
    <time_frame>48 weeks</time_frame>
    <description>Participant bone mineral density of forearm.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Osteoporosis, Postmenopausal</condition>
  <arm_group>
    <arm_group_label>Coral calcium complex and ibandronate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ibandronate and vitamin D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Coral calcium complex</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Coral Complex 3</intervention_name>
    <description>Coral-derived calcium supplement fortified with vitamin D3</description>
    <arm_group_label>Coral calcium complex</arm_group_label>
    <arm_group_label>Coral calcium complex and ibandronate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibandronate</intervention_name>
    <description>Bisphosphonate</description>
    <arm_group_label>Coral calcium complex and ibandronate</arm_group_label>
    <arm_group_label>Ibandronate and vitamin D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <description>Oral vitamin D3</description>
    <arm_group_label>Ibandronate and vitamin D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Postmenopausal women, 50-75 years of age (inclusive). Menopause is defined as no
             menstrual period for 1 year.

          2. BMD T-score of lumbar spine (L1-L4), femoral neck, total hip, or non-dominant forearm
             &lt; -2.5 as determined by DXA.

        Exclusion Criteria:

          1. T-score of lumbar spine, femoral neck, total hip, or non-dominant forearm &lt; -3.5.

          2. Use of any supplemental calcium preparations in the past 1 year.

          3. Use of ibandronate in the past 3 years.

          4. Current use of

               1. prednisone or other corticosteroid,

               2. antiseizure medications,

               3. thiazide diuretics, or

               4. estrogen preparation except vaginal cream.

          5. Electrolyte abnormalities, as defined by abnormal blood levels of sodium (Na),
             chlorine (Cl), potassium (K), phosphate (Phos), calcium (Ca), or magnesium (Mg) values
             on initial screen.

          6. Chronic disease, including

               1. liver disease (as defined by elevated blood levels of aspartate aminotransferase,
                  alanine aminotransferase, and/or alkaline phosphatase or reduced albumin or total
                  protein on initial screen),

               2. stage III renal disease or worse (as defined by epidermal growth factor receptor
                  (eGFR) &lt; 60 cc/min),

               3. abnormal thyroid function tests,

               4. current parathyroid disease (as defined by hypercalcemia and elevated levels of
                  parathyroid hormone (PTH) - if history of hyperparathyroidism, surgical cure has
                  to be documented more than 5 years ago),

               5. diabetes mellitus,

               6. any other known metabolic bone disease besides osteoporosis, and/or

               7. any inflammatory, anatomic, or malabsorptive GI tract disease.

          7. Osteoporotic fracture in the past 6 months, defined as a low-energy fracture such as a
             fracture after falling from a standing height.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John P Bilezikian, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicholas Hutchings, MD</last_name>
    <phone>+1.203.747.6726</phone>
    <email>nicholas.hutchings@uci.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Osteoporosis Center of Armenia</name>
      <address>
        <city>Yerevan</city>
        <country>Armenia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicholas Hutchings, MD</last_name>
      <phone>+1.203.747.6726</phone>
      <email>nicholas.hutchings@uci.edu</email>
    </contact>
    <contact_backup>
      <last_name>Varta Babalyan, MD</last_name>
      <phone>+374.91.411.863</phone>
      <email>vartababalyan@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>John P Bilezikian, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sisak Baghdasaryan, MD, MPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mushegh Kefoyan, MD, MPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Armenia</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 23, 2020</study_first_submitted>
  <study_first_submitted_qc>March 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 25, 2020</study_first_posted>
  <last_update_submitted>March 24, 2020</last_update_submitted>
  <last_update_submitted_qc>March 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>John P. Bilezikian</investigator_full_name>
    <investigator_title>Dorothy L. and Daniel H. Silberberg Professor of Medicine and Professor of Pharmacology</investigator_title>
  </responsible_party>
  <keyword>Calcium</keyword>
  <keyword>Coral calcium</keyword>
  <keyword>Ibandronate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Osteoporosis, Postmenopausal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Ibandronic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

